Arbor Therapeutics, LLC

Other

Case Western Reserve University

Veiled Therapeutics LLC

Mirx Pharmaceuticals, LLC

Invenio Therapeutics Inc.

Mahesh Kumar Gundluru

James D McChesney

Sylesh Kumar Venkataraman

John T Henri

David Wald

Mukesh Agarwal

Goutam Karan

Zhiqing Xia

Zhiqiang Xia

John T Henry

James D Mcchesney

The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders

The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.

HDMX inhibitors and their use for cancer treatment

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents

The present invention relates to use of novel securinine and norsecurine analogs to bind and/or inhibit myeloperoxidase activity.

Small molecule securinine and norsecurinine analogs and their use in inhibiting myeloperoxidase

The present application relates to securinine or norsecurinine analogs that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.

Small molecule securinine and norsecurinine analogs and their use in cancers, inflammatory diseases and infections

The present application discloses new taxane analogs, intermediates and methods for producing them. The present application is also directed to pharmaceutical formulations comprising abeo-taxanes and methods of treating cancer with the abeo-taxanes.

Growing community of inventors

Cordova, TN, United States of America

Mahesh Kumar Gundluru